FDA July 2026 PCAC Meeting Preview: 7 Peptides Up for 503A Reclassification

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is expected to convene in July 2026 to evaluate the regulatory status of at least seven peptide compounds under Section 503A of the Federal Food, Drug, and Cosmetic Act. The compounds anticipated for review — BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax — are among the most frequently nominated bulk drug substances in compounding pharmacy submissions. A determination placing any of these into a restricted category under the 503A bulk drug substances framework would affect their availability through patient-specific compounding channels, with downstream implications for research access across the United States.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

What was announced

The PCAC is the FDA's advisory panel charged with evaluating nominated bulk drug substances for inclusion on the 503A Bulks List — the roster of compounds that licensed compounding pharmacies operating under Section 503A may use as active pharmaceutical ingredients in patient-specific preparations. Substances not placed on this list, or placed in categories indicating they present demonstrable difficulties for compounding, may no longer be available through 503A pharmacies regardless of prescriber intent or patient need.

According to announcements from regulatory law practices tracking the FDA's compounding docket, the July 2026 PCAC meeting agenda is expected to include evaluation of several peptide compounds with significant nominating interest from compounders, clinicians, and researchers. For each compound, the committee is expected to examine clinical need documentation, available evidence, regulatory history, and whether inclusion on the 503A Bulks List is appropriate given existing commercial alternatives.

The 503A framework governs traditional compounding pharmacies that prepare individualized prescriptions on a patient-specific basis. It is distinct from the 503B outsourcing facility framework, which applies to larger-scale, facility-based compounding operations. Both tracks are subject to FDA oversight, but the eligibility criteria and inspection standards differ substantially. A PCAC finding that a compound presents demonstrable preparation difficulties — or that a commercially available FDA-approved equivalent exists — can effectively restrict access to that compound across the entire 503A compounding channel.

Affected compounds

The seven compounds reportedly on the July 2026 agenda span a range of research categories:

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide investigated in preclinical models for tissue repair, angiogenesis, and gastrointestinal healing. Published research documents activity across musculoskeletal and neurological systems, with favorable preclinical safety profiles, though human clinical validation remains limited to small pilot cohorts. There is no FDA-approved commercial BPC-157 equivalent. See the BPC-157 library profile for full compound data.

TB-500 is a synthetic peptide analogue of Thymosin Beta-4, studied for angiogenic and tissue-repair properties in preclinical models. A 2026 narrative review notes that TB-500 "promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both [TB-4 and TB-500] remain banned substances in sports" (PMID 41476424). Its WADA prohibited status and absence of human clinical trials are likely points of discussion in any PCAC evaluation. See the TB-500 library profile.

KPV (Lysine-Proline-Valine) is a tripeptide fragment derived from α-melanocyte-stimulating hormone, investigated for melanocortin receptor signaling and anti-inflammatory properties. A 2026 critical review notes that KPV and similar synthetic fragments appear alongside growth hormone secretagogues in performance-enhancement contexts, with regulatory bodies including WADA monitoring detection challenges due to structural similarity to endogenous peptides (PMID 41880199). See the KPV library profile.

MOTS-c is a mitochondria-derived peptide encoded by the 12S rRNA gene, studied for metabolic regulation and insulin sensitivity. A 2026 clinical study measured serum MOTS-c levels in adolescent populations with metabolic conditions, reflecting growing clinical interest in the peptide's endogenous signaling roles and potential therapeutic applications (PMID 41945630). No FDA-approved MOTS-c preparation currently exists. See the MOTS-c library profile.

DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first characterized in 1974 and subsequently investigated for neuroendocrine regulatory properties, including effects on cortisol release, luteinizing hormone secretion, and sleep architecture modulation. Its compounding nominations have been evaluated as part of broader neuropeptide reviews. No approved commercial equivalent is available in the United States. See the DSIP library profile.

Epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide derived from pineal gland preparations, studied for telomerase activation and cellular aging mechanisms. A 2025 cell biology study demonstrated dose-dependent telomere length extension in normal and cancer cell lines through hTERT upregulation (PMID 41240216). Epitalon is not FDA-approved and has no commercial equivalent in the United States; its 503A eligibility therefore rests entirely on the PCAC nomination review outcome. See the Epitalon library profile.

Semax is a synthetic heptapeptide derived from ACTH(4–7) that is approved for medical use in Russia and has been investigated for neuroprotection, BDNF upregulation, and amyloid pathology reduction in preclinical Alzheimer's disease models (PMID 41479572). Its availability in the United States has depended primarily on compounding channels; the absence of an FDA-approved equivalent makes its 503A classification consequential for domestic research access. See the Semax library profile.

What this changes for research access

If the PCAC recommends, and the FDA subsequently finalizes, a Category 1 determination for any of these compounds, the practical effect would be prohibition of their use as bulk drug substances in 503A compounding. Research institutions and clinicians who currently source these peptides through compounding pharmacies would lose that channel. Because no FDA-approved commercial equivalents exist for most of the compounds listed above, the compounding channel currently represents the only regulated domestic source of research-grade material.

A Category 1 determination does not automatically indicate that a compound has been found unsafe. The classification addresses suitability for patient-specific compounding under the 503A framework — evaluating factors such as whether a suitable commercial alternative exists, whether the compounding use is supported by documented clinical need, and whether the compound presents stability, sterility, or preparation challenges. The resulting practical effect on research access is nonetheless the same: a negative determination removes these compounds from the compounded supply chain under 503A.

Compounds receiving a positive recommendation for continued inclusion would remain on the 503A Bulks List under ongoing review. A favorable outcome for a given peptide would mean the committee found no demonstrable difficulties and identified clinical support for its compounding use, permitting patient-specific preparations to continue.

Timeline and what's next

The anticipated July 2026 PCAC meeting, if held as currently expected, would be followed by a public comment period and FDA deliberation. Final determinations on 503A bulk drug substance eligibility typically follow an advisory committee meeting by several months to over a year, depending on the complexity of the review and the volume of public comments received.

Researchers, research institutions, and clinicians with a stake in the 503A status of these compounds may participate in the public comment process once the PCAC meeting date and associated docket numbers are formally published in the Federal Register. No regulatory determination on any of the seven compounds has been finalized as of the publication date of this article.

External sources

• Orrick LLP — FDA PCAC Compounding Advisory Meeting Announcement: https://www.orrick.com
• Frier Levitt — 503A Bulk Drug Substance PCAC Review Coverage: https://www.frierlevitt.com

Cited studies

• PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians" (Orthopaedic Review, 2026). https://doi.org/10.1517/14712598.2010.490815
• PMID 41880199 — "A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review" (Critical Review, 2026). https://doi.org/10.1016/j.peptides.2009.11.026
• PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (Clinical Study, 2026). https://doi.org/10.1016/j.cmet.2015.01.013
• PMID 41240216 — "Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity" (Cell Biology, 2025). https://doi.org/10.1023/A:1016027606368
• PMID 41479572 — "The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease" (Neuroscience, 2025). https://doi.org/10.1023/A:1010370605929

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.